サインイン
インサイト - Cardiovascular Medicine
Extended Data from APOLLO Phase 1 Trial Demonstrate Sustained Reduction in Lipoprotein(a) with Zerlasiran Treatment
Zerlasiran, a short interfering RNA (siRNA) agent, produces a prolonged and significant reduction in lipoprotein(a) [Lp(a)] levels in adults with elevated Lp(a), including those with atherosclerotic cardiovascular disease (ASCVD).
Novel Antisense Therapy Olezarsen Demonstrates Significant Triglyceride Reduction in Phase 2b Trial
Olezarsen, a novel antisense therapy, significantly reduced triglycerides by approximately 50% compared to placebo in patients with moderate to severe hypertriglyceridemia, with a favorable safety profile.
ApoA1 Infusion Fails to Reduce Cardiovascular Events in Acute MI Patients, But May Benefit Those with High LDL Levels
An ApoA1 infusion product did not significantly reduce the primary composite endpoint of cardiovascular death, myocardial infarction, or stroke in patients with acute MI and additional risk factors. However, an exploratory analysis showed significant benefits in patients with higher baseline LDL levels.
